Addex Therapeutics Ltd
Chemin des Mines 9,
CH-1202 Geneva, Switzerland
January 14, 2022 | Via Edgar |
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Michael Davis Celeste Murphy |
RE: | Addex Therapeutics Ltd Registration Statement on Form F-1 File No. 333-262050 |
Acceleration Request
Requested Date: January 18, 2022
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-262050) (the “Registration Statement”) to become effective on January 18, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Josh Kaufman, counsel to the Registrant, at (212) 479-6495.
Very truly yours,
Addex Therapeutics Ltd.
/s/ Tim Dyer |
Tim Dyer
Chief Executive Officer
cc: | Josh Kaufman, Cooley LLP Marc Recht, Cooley LLP Frank Gerhard, Homburger AG |